Speaker Profile
Ph.D., CEO, CREATE Medicines
Biography
Daniel Getts is a global leader in RNA therapeutics and immune engineering. An Australian-born, US-naturalized scientist and entrepreneur, he is the founder and CEO of multiple biotech ventures, including CREATE Medicines, a clinical-stage company focused on in vivo mRNA immune cell programming, and Aurora Biosynthetics, Australia’s first GMP RNA manufacturing facility, developed in partnership with the NSW Government to strengthen regional biotechnology capability.
Throughout his career, Getts has founded or co-founded several biotechnology companies, including Cour Pharmaceuticals, the field leader in immune tolerance, striking major partnerships with Takeda ($420M) and Genentech ($940M). Collectively, his ventures have generated more than $2 billion USD in value and advanced 11 novel therapies into clinical trials across cancer, autoimmune disease, and transplant rejection.
Getts earned his PhD in Medicine from the University of Sydney and his MBA from Western Michigan University. He conducted postdoctoral research at Northwestern University, where he co-invented multiple immune modulation platforms.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Cindy Perettie, Kite Pharma
PMWC Award Ceremony
• Katy Rezvani, MD Anderson (Luminary)
• David Miklos, Stanford (Luminary)
• Frederick Locke, Moffitt Cancer Center (Luminary)
Featured Speakers
• Katy Rezvani, MD Anderson
• David Miklos, Stanford
• Frederick Locke, Moffitt Cancer Center
• Arie Belldegrun, Allogene Therapeutics
• Paul Hastings, Nkarta Therapeutics
• Priti Hegde, Kite Pharma
• Andrew Scharenberg, Umoja Biopharma
• Brett Staahl, Scribe Therapeutics
• Marcela Maus, Mass General Brigham / Harvard
• Antoni Ribas, UCLA
• Saul Priceman, USC
• Sabine Heitzeneder, Stanford
Off-the-Shelf Cell Therapies
NK, iPSC, and allogeneic T cells: what wins beyond autologous CAR-T.
AI in Cell Therapy: Research to Commercialization
How AI is reshaping discovery, product design, manufacturing, and clinical translation.
The Bottleneck: Manufacturing at Scale
Capacity, automation, cost of goods, and the realities of getting engineered cells to patients.
In Vivo Delivery: The Make-or-Break Layer
Targeting the right tissue safely enough to make in vivo engineering real.
Why Cell Therapies Fail in Solid Tumors and What Works
The microenvironment, antigen escape, and programs showing real responses.
Approved to Effective
Real-world outcomes, access, and what CAR-T still gets wrong after approval.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
